Tezspire Market Report 2026

Tezspire Market Overview

• The Tezspire market growth in the historic period has been driven by increasing prevalence of severe asthma, advancements in monoclonal antibody development • Market expansion is supported by expansion of biologic indications, increasing demand for personalized respiratory therapies • Growth Driver: Rising Prevalence Of Asthma Driving Market Growth Due To Increasing Demand For Targeted Asthma Therapies • Market Trend: Regulatory Approvals Driving Broader Indications For Tezspire In Severe Asthma And Beyond • North America was the largest region in 2025.

What Is Covered Under Tezspire Market?

Tezspire refers to a biologic medication designed to target and inhibit the protein thymic stromal lymphopoietin (TSLP), which plays a key role in the inflammatory processes of respiratory diseases. It is used for the treatment of severe asthma and chronic obstructive pulmonary disease (COPD) to reduce inflammation and improve breathing in patients. The main types of indications in tezspire are asthma, chronic obstructive pulmonary disease, chronic rhinosinusitis, chronic spontaneous urticaria, and eosinophilic esophagitis. Asthma is a chronic condition that causes inflammation and narrowing of the airways, making it difficult to breathe. It is distributed through hospital pharmacies, retail pharmacies, and online pharmacies and caters to end users, including adult patients and pediatric patients.

What Is The Tezspire Market Growth Forecast?

The growth in the forecast period can be attributed to expansion of biologic indications, increasing demand for personalized respiratory therapies, rising investments in immunology drug development, growing focus on early intervention strategies, expansion of advanced asthma treatment guidelines. Major trends in the forecast period include increasing adoption of targeted biologic therapies, rising use of tslp inhibitors in respiratory care, growing focus on severe asthma management, expansion of biologic treatment pipelines, enhanced emphasis on precision immunology.

Global Tezspire Market Segmentation

1) By Indication: Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis, Chronic Spontaneous Urticaria, Eosinophilic Esophagitis 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 3) By End User: Adult Patients, Pediatric Patients

What Are The Drivers Of The Tezspire Market?

The rising prevalence of asthma is expected to propel the growth of the tezspire market going forward. Asthma is a chronic respiratory condition characterized by inflammation and narrowing of the airways, leading to difficulty breathing, wheezing, coughing, and shortness of breath. The rising prevalence of asthma is partly due to increased environmental pollution and lifestyle changes, which contribute to greater exposure to allergens and respiratory irritants. Tezspire is a targeted biologic treatment that helps manage severe asthma by inhibiting a key protein involved in inflammation, reducing exacerbations, and offering relief for patients unresponsive to traditional therapies. For instance, in October 2024, according to the National Asthma Council, an Australia-based non-profit organization, in 2023, Australia recorded a total of 474 asthma-related deaths, comprising 325 females and 149 males. This figure is almost identical to the 473 asthma-related deaths reported in 2022, highlighting a consistent trend in asthma mortality over the two years. Therefore, the increased prevalence of botulism cases is driving growth in the tezspire industry. The rise in clinical trials is expected to propel the growth of the tezspire market going forward. Clinical trials refer to research studies conducted with human participants to evaluate the safety, effectiveness, and potential side effects of medical treatments, interventions, or devices. The increase in clinical trials is driven by advancements in medical research, the demand for personalized treatments, and the need to evaluate new therapies for emerging health conditions and diseases. Clinical trials were crucial in demonstrating tezspire's efficacy and safety, leading to its approval for treating severe asthma and driving its adoption in clinical practice. For instance, in December 2024, according to The Association of the British Pharmaceutical Industry, a UK-based trade association, the total number of industry-sponsored clinical trials initiated in the UK rose from 411 in 2022 to 426 in 2023. Therefore, the rise in clinical trials is driving the growth of the tezspire industry.

Key Players In The Global Tezspire Market

Major companies operating in the tezspire market are AstraZeneca plc, Amgen Inc.

Global Tezspire Market Trends and Insights

Key companies in the tezspire market are gaining regulatory approvals for broader indications, particularly in asthma and potentially other chronic inflammatory conditions. Regulatory approvals refer to the official authorization granted by health authorities, such as the FDA or EMA, allowing a drug or treatment to be marketed and used based on proven safety, efficacy, and quality. For instance, in February 2023, AstraZeneca plc., a UK-based pharmaceutical company, received approval for Tezspire (tezepelumab-ekko) for self-administration using a new pre-filled pen for patients aged 12 and older with severe asthma, in collaboration with Amgen Inc., a US-based biotechnology company. This decision allows patients to administer the medication at home after receiving proper training. The approval is supported by data from the PATHFINDER clinical trial program, where a significant majority of participants successfully self-administered the treatment. Tezspire is unique as it is the first biologic for severe asthma without restrictions based on phenotype or biomarker status, providing a broader treatment option.

Regional Insights

North America was the largest region in the tezspire market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Tezspire Market?

The tezspire market consists of the sales of monoclonal antibodies (mAbs), vaccines, and fusion proteins. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Tezspire Market Report 2026?

The tezspire market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the tezspire industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.